Search results

COVID-19 can’t stop kids with a passion for science and technology, with ANSTO launching our new online STEAM Club just in time for the school holidays.

ANSTO’s nuclear medicine processing and distribution facility assembles, loads, tests and distributes a range of nuclear medicine products, including Mo-99. The Mo-99 is dispensed into an ANSTO radiopharmaceutical Gentech® Generator where it decays to Tc-99m.

A large collaboration of Australian and New Zealand researchers has established that a thin film technology can be used to monitor stormwater effectively and provides a way to translate the presence of metal contaminants into potential risks to aquatic ecosystems.

There is chemistry at work to help us enjoy the New Year's Eve celebration.

A unique scientific capability comprising a single research platform for high-fidelity simulation, real-time dosimetry, and biological response data is available all from a neutron instrument.

Following your experiment at the Australian Synchrotron there are certain tasks that users can complete including a user feedback survey and claiming reimbursement for travel expenses.

The proof of concept for the approach used in the early development of the new gamma-ray imaging system has been published,

ANSTO welcomes the recent announcement that the inaugural CEO for the Australian Radioactive Waste Agency (ARWA) has been appointed, following a global search. Mr Sam Usher will lead ARWA and comes to the role with almost three decades of experience in the nuclear industry. 

The Australian Synchrotron has played a crucial role in the discovery of a new cancer drug for the treatment of leukaemia.

ANSTO User Meeting 2021 - Speakers

The Nobel Prizes for Physics, Chemistry and Medicine have been announced. 

There have been significant developments in small modular reactor technologies in 2022. The International Atomic Energy Agency expects small modular reactors (SMRs) to make an important contribution to achieving global climate goals and energy supply security. But with more than 70 SMR designs under development in 18 countries – including innovative reactors that are yet to be licensed and novel methods of modular manufacturing that are new to the nuclear industry – widely deploying SMRs in time remains a tall task.

Potential new treatments and tools for depression under development.

ANSTO’s Innovation Precinct welcomes NSW Government’s $12.5 commitment funding.